Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Sleep Apnea, Obstructive
Interventions: Seltorexant 40 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor, Licogliflozin, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 28
States / cities: Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Lakes, Florida + 6 more

Conditions: Huntington's Disease
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 47
States / cities: Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Placebo, Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more

Conditions: COVID-19
Interventions: Merimepodib, Matching Placebo, Remdesivir; Drug
Lead sponsor: ViralClear Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more

Conditions: Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Interventions: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 25,236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 156
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more

Conditions: Healthy
Interventions: ABT-384, Matching placebo to ABT-384; Drug
Lead sponsor: Abbott; Industry
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy
Interventions: LY3372689, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiovascular Function in EMTs
Interventions: Antioxidant cocktail, Placebo; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-7309, placebo, Metformin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Pain
Interventions: VX-973, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 45
States / cities: Huntington Park, California • Los Angeles, California • Montclair, California + 42 more

Conditions: Osteoarthritis, Knee
Interventions: CNTX-4975-05, Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more

Conditions: Chronic Heart Failure
Interventions: mRNA-0184, Placebo; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more

Conditions: Healthy Volunteer
Interventions: DSTA4637S, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Anaemia
Interventions: Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more

Conditions: COVID-19
Interventions: Remdesivir (RDV), Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 28
States / cities: Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 20 more

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Opioid Use Disorder
Interventions: Drug Cue, Money, Withdrawal, Remifentanil; Behavioral · Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Mifepristone 600 mg daily, Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Cyproterone acetate 5, Placebo, Cyproterone acetate 15, Cyproterone acetate 25; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 98
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 87 more

Search by objective public record fields.

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

A Safety Study of LY3372689 Given By Mouth to Healthy Participants

Vascular Function and Oxidative Stress in Emergency Medical Responders

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients